Related Experiment Video
Updated: May 3, 2026
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Molecular testing of non-small cell lung carcinoma biopsy and cytology specimens
1From the Departments of Pathology and Thoracic/Head and Neck Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX.
Abstract:
During the past decade, substantial progress has been made in the characterization of molecular abnormalities in non-small cell carcinoma (NSCLC) tumors that are being used as molecular targets and predictive biomarkers for selection of targeted therapy. These recent advances in NSCLC targeted therapy require the analysis of a panel of molecular abnormalities in tumor specimens, including gene mutations (e.g., EGFR, KRAS, BRAF, DDR2), gene amplifications (e.g., MET, FGFR1), and fusions (e.g., EML4-ALK) by applying different methods to tumor tissue (biopsy) and cell (cytology) samples. However, the biopsy and cytology samples available for molecular testing in advanced metastatic NSCLC tumors are likely to be small specimens, including core needle biopsies and/or fine needle aspiration, which may limit the molecular and genomic analysis with currently available methods and technologies. In this process, the role of the pathologist is becoming increasingly important to adequately integrate both routine histopathologic assessment and molecular testing into the clinical pathology for proper tumor diagnosis and subsequent selection of the most appropriate therapy.
Insights
Molecular profiling of non-small cell lung cancer (NSCLC) identifies targets for therapy. Pathologists play a key role in integrating histopathology and molecular testing for accurate diagnosis and treatment selection.
Area of Science:
- Oncology
- Molecular Pathology
- Genomics
Background:
- Significant advancements in characterizing molecular abnormalities in non-small cell lung cancer (NSCLC) have been achieved over the last decade.
- These molecular alterations serve as targets and predictive biomarkers for selecting targeted therapies.
- The analysis of gene mutations, amplifications, and fusions is crucial for personalized NSCLC treatment.
Purpose of the Study:
- To highlight the importance of molecular testing in NSCLC.
- To discuss the challenges associated with molecular analysis of small biopsy and cytology samples.
- To emphasize the evolving role of pathologists in integrating molecular data with histopathology.
Main Methods:
- Review of current molecular testing methodologies for NSCLC.
- Analysis of various molecular abnormalities including gene mutations (EGFR, KRAS, BRAF, DDR2), amplifications (MET, FGFR1), and fusions (EML4-ALK).
- Consideration of different sample types: tumor tissue (biopsy) and cell (cytology) samples.
Main Results:
- Small specimen sizes from biopsies and fine needle aspirations in advanced metastatic NSCLC can limit comprehensive molecular and genomic analysis.
- Current methods and technologies face challenges in fully characterizing molecular profiles from limited samples.
- The integration of histopathologic assessment and molecular testing is essential.
Conclusions:
- The characterization of molecular abnormalities is vital for targeted therapy selection in NSCLC.
- Pathologists are essential in bridging histopathology and molecular diagnostics for optimal patient management.
- Future strategies must address the limitations of analyzing small tissue samples for comprehensive molecular profiling.
More Related Videos
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
10:35A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
Published on: April 5, 2018